Fertility-preserving treatment for patients with malignant germ cell tumors of the ovary

Journal of Obstetrics and Gynaecology Research

Volumn 32, Issue 4, 2006, Pages 416-421

  Nishio, Shin ^a   Ushijima, Kimio ^a   Fukui, Akimasa ^a   Fujiyoshi, Naoki ^a   Kawano, Kouichiro ^a   Komai, Kan ^a   Ota, Shunichiro ^a   Fujiyoshi, Keizo ^a   Kamura, Toshiharu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Fertility preservation; Malignant germ cell tumor; Surgery

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONCEPTION; DYSGERMINOMA; FEMALE; FEMALE FERTILITY; GERM CELL TUMOR; HUMAN; OUTCOME ASSESSMENT; OVARY TUMOR; PREGNANCY; SCHOOL CHILD; SURVIVAL RATE; TERATOMA; YOLK SAC TUMOR;

ADOLESCENT; ADULT; CHILD; FEMALE; FERTILITY; FOLLOW-UP STUDIES; HUMANS; NEOPLASMS, GERM CELL AND EMBRYONAL; OVARIAN NEOPLASMS; OVARIECTOMY;

EID: 33745914661     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2006.00417.x     Document Type: Article

References (35)

1. Gersheson DM. Update on malignant ovarian germ cell tumors. Cancer 1993; 71: 1581-1590.
2. Slayton RE, Park RC, Silverberg SG, Shingleton H, Creasman WT, Blessing JA. Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group Study (a final report). Cancer 1985; 56: 243-248.
3. Segelov E, Campbell J, Ng M et al. Cisplatin-based chemotherapy for ovarian germ cell malignancies: The Australian experience. J Clin Oncol 1994; 12: 378-384.
4. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435-1440.
5. Fishman DA, Schwartz PE. Current approach to diagnosis and treatment of ovarian germ cell malignancies. Curr Opin Obstet Gynecol 1994; 6: 98-104.
6. Schwartz PE, Chambers SK, Chamber JT, Kohorn E, McIntosh S. Ovarian germ cell malignancies: The Yale University experience. Gynecol Oncol 1992; 45: 26-31.
7. Gershenson DM, Del Junco G, Herson J, Rutledge FN. Endodermal sinus tumor of the ovary: The MD Anderson experience. Obstet Gynecol 1983; 61: 194-202.
8. Gershenson DM, Del Junco G, Copeland LJ, Rutledge FN. Mixed germ cell tumors of the ovary. Obstet Gynecol 1984; 64: 200-206.
9. Gershenson DM, Del Junco G, Silva EG, Copeland LJ, Wharton JT. Immature teratoma of the ovary. Obstet Gynecol 1986; 68: 624-629.
10. Buttram VC Jr, Vaqero C. Post-ovarian wedge resection adhesive disease. Fertil Steril 1975; 26: 874.
11. Creaman WT, Soper JT. Assessment of contemporary management of germ cell malignancies of the ovary. Am J Obstet Gynecol 1985; 153: 828-834.
12. Ushijima K, Nishida T, Yakushiji M. Assessment of second-look operations in malignant ovarian germ cell tumors. Int J Gyecol Obstet 1998; 60: 291-292.
13. Einhorn LH, Donohue J. cis-Diamminedichloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977; 87: 293-298.
14. Roth BJ, Greist A, Kubilis PS, Williams SD, Einhorn LH. Cisplatin-based combination chemotherapy for disseminated germ cell tumors: Long-term follow-up. J Clin Oncol 1988; 6: 1239-1247.
15. Gershenson DM, Kavanagh JJ, Copeland LJ et al. Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vinblastine, bleomycin, and cisplatin. Cancer 1986; 57: 1731-1737.
16. Williams SD, Blessing JA, Moore DH, Homesley HD, Adcock L. Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell rumors. A trial of the Gynecologic Oncology Group. Ann Intern Med 1989; 111: 22-27.
17. Sessa C, Bonazzi C, Landoni F, Pecorelli S, Sartori E, Mangioni C. Cisplatin, vinblastine and bleomycin combination chemotherapy in endodermal sinus tumor of the ovary. Obstet Gynecol 1987; 70: 220-224.
18. Williams S, Blessing JA, Liao SY, Ball H, Hanjani P. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: A trial of the Gynecologic Oncology Group. J Clin Oncol 1994; 12: 701-706.
19. Gershenson DM, Morris M, Cangir A, Kavanagh JJ, Stringer CA, Edwards CL. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol 1990; 8: 715-720.
20. Low JJH, Lewis CP, Crandon AJ, Hacker NF. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. Cancer 2000; 89: 391-398.
21. Zanetta G, Bonazzi C, Cantu MG, Binidagger S, Locatelli A, Bratina G. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol 2001; 19: 1015-1020.
22. Abu-Rustum NR, Aghajanian C. Management of malignant germ cell tumors of the ovary. Semin Oncol 1998; 25: 235-242.
23. Horning SJ, Hoppe RT, Kaplan HS, Rosenberg SA. Female reproductive potential after treatment for Hodgkins disease. N Engl J Med 1981; 304: 1377-1382.
24. Andrieu JM, Ochoa-Molina ME. Menstrual cycle, pregnancies and offspring before and after MOPP therapy for Hodgkins disease. Cancer 1983; 52: 435-438.
25. Schilsky RL, Lewis BJ, Sherins RJ, Young RC. Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med 1980; 93: 109-114.
26. Nicosia SV, Matus-Ridley M, Meadows AT. Gonadal effects of cancer therapy in girls. Cancer 1985; 55: 2364-2372.
27. Lai CH, Chang TC, Hsueh S et al. Outcome and prognostic factors in ovarian germ cell malignancies. Gynecol Oncol 2005; 96: 784-791.
28. Nawa A, Obata N, Kikkawa F et al. Prognostic factors of patients with yolk sac tumors of the ovary. Am J Obstet Gynecol 2001; 184: 1182-1188.
29. Nichols CR, Andersen J, Lazarus HM et al. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer. J Clin Oncol 1992; 10: 558-563.
30. Broun ER, Nichols CR, Turns M et al. Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support. Cancer 1994; 73: 1716-1720.
31. Kollmannsberger C, Rick O, Derigs HG et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: A study of the German Testicular Cancer Study Group. J Clin Oncol 2002; 20: 2031-2037.
32. Motzer RJ, Bajorin DF, Schwartz LH et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994; 12: 2277-2283.
33. Einhorn LH, Stender MJ, Williams SD. Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol 1999; 17: 509-511.
34. Messing MJ, Gershenson DM, Morris M et al. Primary treatment failure in patients with malignant ovarian germ cell neoplasms. Int J Gynecol Cancer 1992; 2: 295-300.
35. Munkarah A, Gershenson DM, Levenback C et al. Salvage surgery for chemorefractory ovarian germ cell tumors. Gynecol Oncol 1994; 55: 217-223.